AIM ImmunoTech Files S-1 for Public Offering

TL;DR

AIM ImmunoTech files S-1, looks to raise cash via public offering.

AI Summary

AIM ImmunoTech Inc. filed an S-1 registration statement with the SEC on November 15, 2024, to register securities for public sale. The company, formerly known as Hemispherx Biopharma Inc., is based in Ocala, Florida, and operates in the biological products sector. This filing indicates a potential offering of new shares or other securities to raise capital.

Why It Matters

This S-1 filing signals AIM ImmunoTech's intention to raise capital through the public markets, which could fund further research and development or expansion of its business operations.

Risk Assessment

Risk Level: medium — S-1 filings often precede stock offerings, which can dilute existing shareholders or indicate the company needs capital for operations or growth, carrying inherent investment risks.

Key Numbers

• 333-283269 — SEC File Number (Identifies this specific registration statement)
• 2836 — SIC Code (Indicates industry classification (Biological Products))

Key Players & Entities

• AIM ImmunoTech Inc. (company) — Registrant
• November 15, 2024 (date) — Filing Date
• Hemispherx Biopharma Inc. (company) — Former Company Name
• Ocala, Florida (location) — Principal Executive Offices
• Thomas K. Equels (person) — Chief Executive Officer
• Richard Feiner, Esq. (person) — Agent for Service Counsel
• Silverman, Shin & Schneider PLLC (company) — Counsel

FAQ

Key Financial Figures

• $0.001 — 6,072 shares of common stock, par value $0.001 per share (the “Common Stock&rdqu
• $0.24 — r Common Stock on the NYSE American was $0.24 per share. Investing in our Common St
• $250 million — ny and have a public float of less than $250 million or annual revenues of less than $100 mi
• $100 million — million or annual revenues of less than $100 million during the most recently completed fisc
• $18.57 — at a weighted average exercise price of $18.57 per share; and 2,814,142 shares of our
• $1.54 — at a weighted average exercise price of $1.54 per share; 1,474,482 shares of our Co
• $0.363 — at a weighted average exercise price of $0.363 per share; and 360,000 shares of our
• $2,605,700 — for cash, we will receive approximately $2,605,700 in gross proceeds. We intend to use the

Filing Documents

• forms-1.htm (S-1) — 440KB
• ex5-1.htm (EX-5.1) — 25KB
• ex23-1.htm (EX-23.1) — 6KB
• ex107.htm (EX-FILING FEES) — 25KB
• forms-1_001.jpg (GRAPHIC) — 18KB
• 0001493152-24-046305.txt ( ) — 522KB

USE OF PROCEEDS

USE OF PROCEEDS 3 DIVIDEND POLICY 3 DETERMINATION OF THE OFFERING PRICE 3

DESCRIPTION OF CAPITAL STOCK

DESCRIPTION OF CAPITAL STOCK 3 DESCRIPTION OF THE PRIVATE PLACEMENT 5 SELLING STOCKHOLDER 6 PLAN OF DISTRIBUTION 7 LEGAL MATTERS 8 EXPERTS 8 INCORPORATION OF CERTAIN INFORMATION BY REFERENCE 8 WHERE YOU CAN FIND MORE INFORMATION 8 i ABOUT THIS PROSPECTUS You should rely only on the information we have provided or incorporated by reference into this prospectus and any related free writing prospectus. We have not authorized anyone to provide you with information different from that contained in this prospectus, any applicable prospectus supplement or any related free writing prospectus. No dealer, salesperson or other person is authorized to give any information or to represent anything not contained in this prospectus, any applicable prospectus supplement or any related free writing prospectus. You must not rely on any unauthorized information or representation. This prospectus is an offer to sell only the shares of Common Stock offered hereby, but only under circumstances and in jurisdictions where it is lawful to do so. You should assume that the information in this prospectus or any related free writing prospectus is accurate only as of the date on the front of the document and that any information we have incorporated by reference is accurate only as of the date of the document incorporated by reference, regardless of the time of delivery of this prospectus or any sale of a security. This prospectus and the documents incorporated by reference into this prospectus include statistical and other industry and market data that we obtained from industry publications and research, surveys and studies conducted by AIM, by third parties, or by third parties in collaboration with AIM. Industry publications and research, surveys and studies generally indicate that their information has been obtained from sources believed to be reliable, although they do not guarantee the accuracy or completeness of such information. We believe that the data obt

View Full Filing

View this S-1 filing on SEC EDGAR